News
The day at a glance · 2 min read
Market mood
—
Sentiment, −100 to +100
Daily briefHealthcare· Money365.Market AI ·

M&A Wave Hits Healthcare as Regulatory Focus Sharpens

Gilead and Merck strike deals while UnitedHealth faces antitrust scrutiny

Healthcare Market Overview

Healthcare stocks showed mixed performance with several major names experiencing recent pullbacks. $ABT closed around $104 after declining 16.2% year to date, while $ISRG traded at $471.91 following a 16.0% YTD decline. $AMGN shares pulled back 7% over the past month to $348.43, though maintained a positive 6.35% YTD return.

Big Pharma & Biotech

$GILD announced a $2.2 billion acquisition of Ouro Medicines to expand beyond HIV and oncology into autoimmune diseases, marking its entry into T-cell engager assets. $MRK signed a multiyear research collaboration with Quotient Therapeutics focused on inflammatory bowel disease genetics, with milestones worth up to $2.2 billion and a $20 million upfront payment. $ABBV expanded its psychiatry pipeline through the 2025 acquisition of bretisilocin from Gilgamesh Pharmaceuticals for $1.2 billion, adding a Phase 2 psychedelic candidate for major depressive disorder. $PFE gained attention for recent clinical wins in oncology and a promising obesity pipeline despite looming patent cliffs.

MedTech & Devices

$ISRG is acquiring the da Vinci and Ion distribution business in Southern Europe to gain direct control over sales and service for its robotic-assisted surgery platforms in the region. $JNJ received FDA approval for its TECNIS PureSee intraocular lens, an extended depth of focus option for cataract surgery targeting presbyopia and visual clarity. The company also reported positive first-in-human Phase 1 results for an extended release erdafitinib delivery system in non-muscle invasive bladder cancer.

FDA & Regulation

$UNH now faces concentrated regulatory scrutiny as the sole remaining defendant in the FTC's antitrust lawsuit against pharmacy benefit managers after CVS Health reached a proposed settlement. The company, trading at $272.28, confronts increased government focus on its PBM operations and role in the broader case. No PDUFA dates or advisory committee votes were reported in today's news cycle.

Looking Ahead

The GLP-1 market remains a focal point with analysts rating both Novo Nordisk and Eli Lilly as holds amid valuation debates, though market narratives may not fully support current fundamentals. Kroger pharmacies began offering $LLY's Zepbound KwikPen weight-management medication with access support and savings programs. The ongoing consolidation trend in pharma suggests continued M&A activity as companies seek to diversify pipelines and enter new therapeutic areas.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy